Amgen Inc. (NASDAQ:AMGN) is included among the 15 Blue Chip Dividend Stocks to Build a Passive Income Porfolio. On December 3 ...

Looking toward dividend payers is a particularly good idea, because companies that consistently increase their payouts tend ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of millions of patients who’ve lost unprecedented amounts of weight. On ...

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), AT&T Inc. (T) ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.